Saturday 17 October 2026
Export ABCL’s income statement to Excel — free account
AbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 50.0% and free cash flow grew 152.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.80
0.88
−6.94%
Follow ABCL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
36.25 | 13.35 | 13.60 | 42.56 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
92.53 | (31.55) | (29.40) | (28.58) | |
P/B ratio |
2.68 | 1.13 | 1.06 | 1.56 | |
Price to Tangible BV |
2.96 | 1.24 | 1.16 | 1.71 | |
EV/Sales |
27.76 | 6.71 | 6.21 | 27.92 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(19.35) | (3.47) | (3.55) | (9.43) | |
EV/FCF |
(14.96) | (2.76) | (2.63) | (6.31) | |
Quick Ratio |
10.97 | 11.98 | 9.60 | 8.17 | |
Current Ratio |
12.77 | 14.05 | 11.32 | 10.10 | |
Net Debt/EBITDA |
10.47 | 10.84 | 27.05 | 7.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.06 | 0.06 | 0.03 | |
Operating CF/Net income |
(0.47) | 0.78 | 3.88 | 0.92 | |
Capex/Depreciation |
(0.24) | (0.44) | (1.24) | (1.23) | |
Research and Development Expense of Revenue |
1,135.48% | 561.18% | 111.68% | 614.49% | |
Selling, General and Administrative Expense of Revenue |
341.98% | 148.33% | 38.39% | 278.70% | |
Intangible Assets out of Total Assets |
0.06 | 0.07 | 0.06 | 0.06 | |
Share Based Compensation of Revenue |
303.36% | 144.47% | 28.77% | 155.16% | |
Graham Net Nets |
0.11 | 0.28 | 0.33 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.88%) | (13.75%) | (14.33%) | (11.33%) | |
Free Cash Flow Yield |
(5.12%) | (18.19%) | (17.34%) | (10.39%) | |
Revenue per Share |
0.01 | 0.03 | 0.15 | 0.03 | |
Operating CF per Share |
0.08 | (0.11) | (0.12) | (0.18) | |
Capex per Share |
(0.01) | (0.01) | (0.03) | (0.03) | |
Free Cash Flow per Share |
0.08 | (0.12) | (0.15) | (0.21) | |
Cash per Share |
1.85 | 1.75 | 1.87 | 1.74 | |
Shareholders Equity per Share |
2.93 | 3.10 | 3.24 | 3.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.93 | 3.10 | 3.24 | 3.23 | |
Free Cash Flow |
23.79 | (37.35) | (44.59) | (61.52) | |
Working Capital |
626.04 | 617.30 | 663.93 | 626.34 | |
Capital Expenditures |
(2.13) | (3.83) | (9.84) | (8.93) | |
Net Current Asset Value |
267.68 | 295.57 | 338.19 | 303.19 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.53 | 0.46 | 0.22 | 1.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
32.95 | 38.38 | 45.95 | 36.41 | |
Average Payables |
41.28 | 43.70 | 52.89 | 53.45 | |
Average Assets |
1,354.82 | 1,325.66 | 1,358.75 | 1,374.41 | |
Average Common Equity |
951.55 | 980.53 | 1,011.49 | 1,021.07 |
Columns are period end dates